Differential regulation of hepatic macrophage fate by Chi3l1 in metabolic dysfunction-associated steatotic liver disease
eLife · 2026
DOI: 10.7554/elife.107023 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Jia He und 15 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China. Hauptthemen laut MEDLINE: Chitinase-3-Like Protein 1, Kupffer Cells, Macrophages, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Yunnan Province Science and Technology Department.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) progression involves the replacement of protective embryo-derived Kupffer cells (KCs) by inflammatory monocyte-derived macrophages (MoMFs), yet the regulatory mechanisms remain unclear. Here, we identify chitinase 3-like 1 (Chi3l1/YKL-40) as a critical metabolic regulator of hepatic macrophage fate. We observed high expression of Chi3l1 in both KCs and MoMFs during MASLD development. Genetic deletion of Chi3l1 specifically in KCs significantly exacerbated MASLD severity and metabolic dysfunction, whereas MoMF-specific Chi3l1 deletion showed minimal metabolic effects. Mechanistic studies revealed that this cell type-specific regulation arises from differential metabolic requirements: KCs display elevated glucose metabolism compared to MoMFs. Chi3l1 directly interacts with glucose to inhibit its cellular uptake, thereby selectively protecting glucose-dependent KCs from metabolic stress-induced cell death while having negligible effects on less glucose-dependent MoMFs. These findings uncover a novel Chi3l1-mediated metabolic checkpoint that preferentially maintains KCs populations through glucose metabolism modulation, providing important new insights into the pathogenesis of MASLD and potential therapeutic strategies targeting macrophage-specific metabolic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China.
- Bio-X Center for Interdisciplinary Innovation, Yunnan University, Kunming, China.
ORCID-Profile: Zhao Shan
Förderung
- National Natural Science Foundation of China
- Yunnan Province Science and Technology Department
Zitieren
APA
He, J., Chen, B., Lu, W., Wang, X., Yang, R., Deng, C., Zhu, X., Wang, K., Wang, L., Xie, C., Li, R., Lu, X., Yang, R., Peng, C., Li, C., & Shan, Z. (2026). Differential regulation of hepatic macrophage fate by Chi3l1 in metabolic dysfunction-associated steatotic liver disease. eLife. https://doi.org/10.7554/elife.107023
Vancouver
He J, Chen B, Lu W, Wang X, Yang R, Deng C, et al. Differential regulation of hepatic macrophage fate by Chi3l1 in metabolic dysfunction-associated steatotic liver disease. eLife. 2026. doi:10.7554/elife.107023
BibTeX
@article{He2026,
author = {He, Jia and Chen, Bo and Lu, Weiju and Wang, Xiong and Yang, Ruoxue and Deng, Chengxiang and Zhu, Xiane and Wang, Keqin and Wang, Lang and Xie, Cheng and Li, Rui and Lu, Xiaokang and Yang, Ruizhi and Peng, Cheng and Li, Canpeng and Shan, Zhao},
title = {Differential regulation of hepatic macrophage fate by Chi3l1 in metabolic dysfunction-associated steatotic liver disease},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.107023}
}
EUVIMED